ONE NUCLEUS STRENGTHENS BOARD WITH APPOINTMENT OF NEW DIRECTOR

Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024

Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024
Amsbio report how its biospecimens were used in a large-scale immuno-oncology study analysing Fibroblast Activation protein (FAP) expression across 23 tumour types, contributing to new insights into biomarker development for cancer immunotherapies.
Never losing sight of our purpose
Mestag Therapeutics is a clinical-stage biotechnology company pioneering the discovery and development of antibody therapeutics targeting cancer and inflammatory disease. Our science is rooted in fibroblast immunology, leveraging cutting-edge biological and translational insights to uncover novel pathways that drive immune modulation in disease.
Mestag is backed by committed leading global investors, has world-class founders and a highly experienced leadership team.
Your key responsibilities:
The Centre for Protein Degradation (CPD), led by Professor Zoran Rankovic, is a recently established centre at the ICR dedicated to discovering and developing novel cancer treatments through targeted protein degradation.
Boyds, a leading global drug development consultancy, is pleased to announce the appointment of Laurence Skillern as Chief Medical Officer.
Overview
The pharmaceutical and life sciences sector is changing fast. AI is accelerating drug discovery. Automation is reshaping the lab. Sustainability is no longer optional. This event puts you at the centre of it all.